JP2021520396A - 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤 - Google Patents

閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤 Download PDF

Info

Publication number
JP2021520396A
JP2021520396A JP2020555145A JP2020555145A JP2021520396A JP 2021520396 A JP2021520396 A JP 2021520396A JP 2020555145 A JP2020555145 A JP 2020555145A JP 2020555145 A JP2020555145 A JP 2020555145A JP 2021520396 A JP2021520396 A JP 2021520396A
Authority
JP
Japan
Prior art keywords
bos
composition
use according
csa
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555145A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019197406A5 (https=
JP2021520396A5 (https=
Inventor
オリファー デンク，
オリファー デンク，
ゲルハルド ブルナー，
ゲルハルド ブルナー，
アルド イアコノ，
アルド イアコノ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Breath Therapeutics GmbH
Original Assignee
Breath Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Therapeutics GmbH filed Critical Breath Therapeutics GmbH
Publication of JP2021520396A publication Critical patent/JP2021520396A/ja
Publication of JPWO2019197406A5 publication Critical patent/JPWO2019197406A5/ja
Publication of JP2021520396A5 publication Critical patent/JP2021520396A5/ja
Priority to JP2024035414A priority Critical patent/JP2024069355A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020555145A 2018-04-11 2019-04-09 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤 Pending JP2021520396A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024035414A JP2024069355A (ja) 2018-04-11 2024-03-07 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862656226P 2018-04-11 2018-04-11
US62/656,226 2018-04-11
EP18172067 2018-05-14
EP18172067.3 2018-05-14
PCT/EP2019/058958 WO2019197406A1 (en) 2018-04-11 2019-04-09 Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024035414A Division JP2024069355A (ja) 2018-04-11 2024-03-07 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤

Publications (3)

Publication Number Publication Date
JP2021520396A true JP2021520396A (ja) 2021-08-19
JPWO2019197406A5 JPWO2019197406A5 (https=) 2022-04-18
JP2021520396A5 JP2021520396A5 (https=) 2022-04-18

Family

ID=66049232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555145A Pending JP2021520396A (ja) 2018-04-11 2019-04-09 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤
JP2024035414A Pending JP2024069355A (ja) 2018-04-11 2024-03-07 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024035414A Pending JP2024069355A (ja) 2018-04-11 2024-03-07 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤

Country Status (21)

Country Link
US (4) US11484566B2 (https=)
EP (2) EP4400119A3 (https=)
JP (2) JP2021520396A (https=)
CN (1) CN112105374A (https=)
AU (1) AU2019253137B2 (https=)
BR (1) BR112020020564A2 (https=)
CA (1) CA3094891A1 (https=)
CO (1) CO2020013427A2 (https=)
DK (1) DK3773664T3 (https=)
ES (1) ES2980198T3 (https=)
FI (1) FI3773664T3 (https=)
HR (1) HRP20241022T1 (https=)
HU (1) HUE067518T2 (https=)
IL (1) IL277253B2 (https=)
LT (1) LT3773664T (https=)
MX (1) MX2020010738A (https=)
PL (1) PL3773664T3 (https=)
RS (1) RS65713B1 (https=)
SI (1) SI3773664T1 (https=)
SM (1) SMT202400220T1 (https=)
WO (1) WO2019197406A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
HRP20241022T1 (hr) * 2018-04-11 2024-11-08 Breath Therapeutics Gmbh Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos)
US10736847B2 (en) 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation
CN114642677A (zh) * 2020-12-21 2022-06-21 上海凯屹医药科技有限公司 一种稳定的含有苦丁皂苷类化合物的液体药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180042988A1 (en) * 2015-03-16 2018-02-15 Pari Pharma Gmbh Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
HRP20241022T1 (hr) * 2018-04-11 2024-11-08 Breath Therapeutics Gmbh Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180042988A1 (en) * 2015-03-16 2018-02-15 Pari Pharma Gmbh Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEHR, J. ET AL.: "Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplanta", JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, vol. 22, no. 2, JPN6023017771, 2009, pages 121 - 130, ISSN: 0005049495 *
FAKHRO, M. ET AL.: "Double lung, unlike single lung transplantation might provide a protective effect on mortality and b", JOURNAL OF CARDIOTHORACIC SURGERY, vol. 12, no. 1, JPN6024026192, 2017, pages 100, ISSN: 0005358864 *
IACONO, A. ET AL.: "(211) - Stabilization of Lung Function and Survival Improvement By Aerosolized Liposomal Cyclosporin", THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. Vol. 37, No. 4, Supplement, JPN6023017772, 31 March 2018 (2018-03-31), pages 91 - 92, ISSN: 0005358862 *
NEUROHR, C. ET AL.: "Potential functional and survival benefit of double over single lung transplantation for selected pa", TRANSPLANT INTERNATIONAL, vol. 23, no. 9, JPN6024026193, 2010, pages 887 - 896, ISSN: 0005358863 *

Also Published As

Publication number Publication date
US11484566B2 (en) 2022-11-01
HRP20241022T1 (hr) 2024-11-08
CN112105374A (zh) 2020-12-18
PL3773664T3 (pl) 2024-09-02
US20230364182A1 (en) 2023-11-16
CA3094891A1 (en) 2019-10-17
WO2019197406A1 (en) 2019-10-17
US20230128855A1 (en) 2023-04-27
JP2024069355A (ja) 2024-05-21
IL277253B1 (en) 2023-12-01
FI3773664T3 (fi) 2024-07-16
SI3773664T1 (sl) 2024-08-30
LT3773664T (lt) 2024-06-10
IL277253A (en) 2020-10-29
US12178843B2 (en) 2024-12-31
SMT202400220T1 (it) 2024-07-09
CO2020013427A2 (es) 2020-11-10
BR112020020564A2 (pt) 2021-01-12
ES2980198T3 (es) 2024-09-30
RS65713B1 (sr) 2024-08-30
DK3773664T3 (da) 2024-06-17
AU2019253137A1 (en) 2020-11-05
IL277253B2 (en) 2024-04-01
EP4400119A2 (en) 2024-07-17
EP4400119A3 (en) 2024-09-25
AU2019253137B2 (en) 2025-01-30
US11701403B2 (en) 2023-07-18
EP3773664A1 (en) 2021-02-17
HUE067518T2 (hu) 2024-10-28
MX2020010738A (es) 2020-11-09
US20210077573A1 (en) 2021-03-18
EP3773664B1 (en) 2024-05-01
US20250090625A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
US12178843B2 (en) Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS)
US11744872B2 (en) Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
RU2421209C2 (ru) Фармацевтические композиции, содержащие циклоспорин
US9987227B2 (en) Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
KR20170005104A (ko) 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
JP6840869B2 (ja) 肺障害の治療方法
US9248110B2 (en) Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
CA2483917A1 (en) Formulations limiting spread of pulmonary infections
EP2467715A1 (en) Riboflavin based aerosol and use as placebo in trials
JP7401471B2 (ja) 凍結乾燥形態の医薬組成物
EA047564B1 (ru) Составы циклоспорина для применения для лечения синдрома облитерирующего бронхиолита (bos)
BR112017018339B1 (pt) Uso de uma formulação líquida de ciclosporina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240321

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413